Clinical Trial Update: DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating DV in combination with cadonilimab for HER2-expressing gastric cancer and gastroesophageal junction adenocarcinoma after progression …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Cadonilimab
• DV

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2, Phase 3 | Status: RECRUITING